EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN
〰️
EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN 〰️
Most of the current tumor-targeted antibodies only serve a subset of patients and a subset of cancers. Many of them also unintentionally target healthy tissues, causing severe side effects.
“We aim to become the leading provider of truly tumor-specific mAb-based therapies. Our solution is for all cancer patients, across all cancer types, without targeting healthy cells.
We will pioneer the future of anti-cancer therapy! ”
OUR MISSION
The iDEAL discovery of high affinity combotope antibodies
Sugars (glycans) play a crucial role in modifying many essential proteins in our bodies, including those found on the surfaces of cancer cells. In most cancers, these sugar structures are shortened compared to healthy cells, offering a unique opportunity to differentiate between cancerous and normal cells.
Combotope Therapeutics proprietary mAb discovery platform is designed to target cancer cells without impacting healthy cells. Our integrated Design Antibody Libraries (iDEAL), combines glycan and peptide-focused scFv technology, providing antibodies with pM affinities that specifically target the tumor form of a particular protein on cancer cells while leaving healthy cells untouched. Our scFv sequences are compatible with numerous therapeutic modalities for effective cancer treatment.
We offer an attractive partnership business model.
We identify, develop, and license proprietary scFv sequences that specifically target cancer proteins with aberrant O-glycosylation.
Through strategic partnerships, we advance the development and commercialization of pioneering scFv-based off-the-shelf and personalized anti-cancer therapies.
Our combined tumor glycan-protein targeting strategy allows revisiting current targets, previously intractable and abandoned targets, as well as new targets discovered by partners or from new academic discoveries.
EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN, LAG-3, Fn14, S1PR3, ..and many more
Our proprietary iDEAL discovery platform allows identification of unique, patentable scFv sequences dictated by aberrantly glycosylated protein targets. This provides scFv fragments with superior benefits for our partners:
Novel class of mAbs
Cancer selective
Target specific
High affinity
No targeting of healthy tissue.
Untouched IP space
Our scFv antibody format provides customized Plug'N'Play solutions for our partners and enables the development of pioneering anti-cancer treatment modalities.
IgG mAb
ADC
CAR-T
BiTE’s
Immunocytokine
Radiolabeled
And more
We offer an attractive partnership business model that advances win-win relationships.
Upfront, and milestone payments tied to development and regulatory achievements
Minimum royalties and royalties based on product sales.
Management
-
Dr. Klas Ola Blixt
CO-FOUNDER, INVENTOR, & CEO
Ola is the inventor of the Combotope concept and possesses a profound understanding of aberrant glycosylation, enabling the generation of cancer-specific and cancer-selective antibodies. With over 20 years of experience in both basic and applied research across fields such as chemical biology, glycoscience, monoclonal antibodies, and biomarkers, Ola has produced several highly cited publications (h=50) and holds numerous patents. Moreover, Ola brings more than 15 years of management and leadership experience to the table.
-
Dr. Søren Nyboe Jakobsen
CO-FOUNDER, COO
Søren is an inventor/co-inventor of patents related to molecular display and molecular selection techniques, as well as technologies for the detection and characterization of B-, and T cells. Most recently, Søren was the founder and CEO of Tetramer Shop (acquired by 10x Genomics). He has previously created foundational IP, platforms, products, and services at notable companies such as Novo Nordisk, Nuevolution (acquired by Amgen), Immudex, PokeACell, and 10x Genomics. Søren has extensive management and leadership experience.
Science Advisors
-
Professor Andreas H. Laustsen-Kiel
Co-founder, Center for Antibody Technologies, DTU Bioengineering
-
Professor Richard Cummings
Tumor glycobiology, Harvard Medical School Department of Surgery
-
Professor Ramon Hurtado Guerrero
Co-inventor, Structural biology, University of Zaragoza
-
Professor Nico Callewaert
Director, VIB Center for Medical Biotechnology, Biochemistry and Biotechnology, UGent
Book a tee time with us, and we'll provide you with further details on glycosylation, our company, and the potential for collaboration.
Messi is our Chief Bonding Officer (CBO). He's been an amazing team member, but we're opening the leash to new applicants at Combotope. Don't worry, Messi's totally cool with it – he's all excited about our animal-free solutions. So, if you're ready let's chat!
Combotope Therapeutics ApS
Diplomvej 381
DK-2800 Kongens Lyngby
Denmark
Contact:
olablixt@combotope.com
Company registration (CVR) no. 44308266